Infliximab (anti-tumor necrosis factor α antibody): A novel, highly effective treatment of recalcitrant subcorneal pustular dermatosis (Sneddon-Wilkinson disease)

Archives of Dermatology

Volumn 137, Issue 12, 2001, Pages 1571-1574

  Voigtländer, Constanze ^a   Lüftl, Matthias ^a   Schuler, Gerold ^a   Hertl, Michael ^a,b  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b Department of Dermatology ^*  (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ALPHA TOCOPHEROL; AZATHIOPRINE; COLCHICINE; DAPSONE; ETRETIN; GLUCOCORTICOID; INFLIXIMAB; MEBHYDROLIN; MEPREDNISONE; METHOTREXATE; RETINOID; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

AGED; ARTICLE; BREAST CANCER; CASE REPORT; DRUG EFFICACY; FEMALE; GERIATRIC PATIENT; HEMOLYTIC ANEMIA; HERPES SIMPLEX; HUMAN; HUMAN TISSUE; IMMUNOTHERAPY; PHOTOTHERAPY; PRIORITY JOURNAL; PUSTULE; SKIN BIOPSY; SKIN DISEASE; SUBCORNEAL PUSTULAR DERMATOSIS;

AGED; ANTIBODIES, MONOCLONAL; ARM; BREAST NEOPLASMS; C-REACTIVE PROTEIN; DERMATOLOGIC AGENTS; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LEUKOCYTE COUNT; SKIN DISEASES, VESICULOBULLOUS; THORAX; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0035664971     PISSN: 0003987X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Folkers E, Tafelkruyer J. Subcorneal pustular dermatosis (Sneddon-Wilkinson disease): therapeutic problems. Br J Dermatol. 1978;98:681-684.
2. Sneddon IB, Wilkinson DS. Subcorneal pustular dermatosis. Br J Dermatol. 1956; 68:385-394.
3. Orton DI, George SA. Subcorneal pustular dermatosis responsive to narrow-band (TL-01) UVB phototherapy. Br J Dermatol. 1997;137:149-150.
4. Todd DJ, Bingham EA, Walsh M, Burrow D. Subcorneal pustular dermatosis and IgA paraproteinaemia: response to both etretinate and PUVA. Br J Dermatol. 1991; 125:387-389.
5. Iandoli R, Monfrecola G. Treatment of subcorneal pustulosis by etretinate. Dermatologica. 1987;175:235-238.
6. Dorittke P, Wassilew SW. Subcorneale Pustulose Sneddon Wilkinson: Therapie mit Mebhydrolin. Z Hautkr. 1988;63:1025-1027.
7. Kaufmann J, Gilliet F, Ott F, Wüthrich B. Subcornale Pustulosis Sneddon-Wilkinson. Dermatologica. 1975;150:238-242.
8. Marsden JR, Millard LG. Pyoderma gangrenosum, subcorneal pustular dermatosis and IgA paraproteinaemia. Br J Dermatol. 1986;114:125-129.
9. Butt A, Burge SM. Sneddon-Wilkinson disease in association with rheumatoid arthritis. Br J Dermatol. 1995;132:313-315.
10. Wilkinson DS. Subcorneal pustular dermatosis. Bull Soc Fr Dermatol Syphiligr. 1962;69:674-679.
11. Targan SR, Hanauer SB, van Deventer SJ, et al for the Crohn's Disease cA2 Study Group. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. N Engl J Med. 1997;337:1029-1035.
12. Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med. 1999;340:1398-1405.
13. Geyer AS, Anhalt GJ, Nousari HC. Effectiveness of infliximab in the treatment of refractory perineal cutaneous Crohn disease. Arch Dermatol. 2000;136:459-460.
14. Maini R, St Clair EW, Breedveld F, et al. Infliximab (chimeric anti-tumor necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. Lancet. 1999; 354:1932-1939.
15. Cream JJ, Grimes SM, Roberts PD. Subcorneal pustulosis and IgA myelomatosis. BMJ. 1977;1:550.
16. Grob JJ, Mege JL, Capo C, et al. Role of tumor necrosis factor-α in Sneddon-Wilkinson subcorneal pustular dermatosis. J Am Acad Dermatol. 1991;25:944-947.
17. Shalaby MR, Palladino MA Jr, Hirabayashi SE, et al. Receptor binding and activation of polymorphonuclear neutrophils by tumor-necrosis factor-alpha. J Leukoc Biol. 1987;41:196-204.
18. Knight DM, Trinh H, Le J, et al. Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Mol Immunol. 1993;30:1443-1453.
19. Ogilvie ALJ, Antoni CH, Dechant C, et al. Treatment of psoriatic arthritis with anti-TNF-α antibody clears skin lesions of psoriasis resistant to treatment with methotrexate. Br J Dermatol. 2001;144:587-589.
20. Oh CJ, Das KM, Gottlieb AB. Treatment with anti-tumor necrosis factor α (TNF-α) monoclonal antibody dramatically decreases the clinical activity of psoriasis lesions. J Am Acad Dermatol. 2000;42:829-830.